Novo Nordisk Securities Class Action Lawsuit Deadline Set for Sept. 30, 2025.

Rosen Law Firm reminds Novo Nordisk A/S (NVO) investors of the September 30, 2025 lead plaintiff deadline for a class action lawsuit filed on behalf of those who purchased securities between May 7 and July 28, 2025. Investors who bought NVO securities during this period may be entitled to compensation without out-of-pocket fees or costs through a contingency fee arrangement. To join the lawsuit, visit https://rosenlegal.com/submit-form/?case_id=34168 or call Phillip Kim at 866-767-3653.

Investors who purchased Novo Nordisk A/S (NVO) securities between May 7, 2025, and July 28, 2025, are reminded of the approaching September 30, 2025, deadline to serve as lead plaintiff in a class action lawsuit. Rosen Law Firm, a global investor rights law firm, has notified investors of this opportunity to seek compensation for alleged securities fraud [1].

The lawsuit, filed on behalf of investors who bought NVO securities during the specified period, claims that Novo Nordisk made materially false and misleading statements about its growth potential. The firm's statements reportedly overstated the impact of the personalization exception to the compounded GLP-1 exclusion and misrepresented the likelihood of patients transitioning to Novo Nordisk's branded alternatives. Additionally, the lawsuit alleges that Novo Nordisk significantly overstated the size of the GLP-1 market and its ability to penetrate that market [2].

Investors who wish to participate in the class action can join by visiting [Rosen Law Firm's website](https://rosenlegal.com/submit-form/?case_id=34168) or by contacting Phillip Kim, Esq., at 866-767-3653. The Rosen Law Firm represents investors worldwide and has a proven track record in securities class actions, recovering hundreds of millions of dollars for investors [3].

References:
[1] Rosen Law Firm. (2025, Aug. 31). Rosen Global Investor Counsel Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action NVO. Retrieved from https://www.globenewswire.com/news-release/2025/09/01/3141946/673/en/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Novo-Nordisk-A-S-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-NVO.html
[2] Rosen Law Firm. (2025, Sept. 2). NVO Investors Have Opportunity to Lead Novo Nordisk as Securities Fraud Lawsuit. Retrieved from https://www.prnewswire.com/news-releases/nvo-investors-have-opportunity-to-lead-novo-nordisk-as-securities-fraud-lawsuit-302543340.html
[3] Bronstein, Gewirtz & Grossman, LLC. (2025, Sept. 1). NVO Investor Alert: Bronstein Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit. Retrieved from https://www.globenewswire.com/news-release/2025/09/01/3142280/9788/en/NVO-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Novo-Nordisk-A-S-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html